US2017216260A1PendingUtilityA1
Oxazole compound and pharmaceutical composition
Est. expiryNov 15, 2025(expired)· nominal 20-yr term from priority
Inventors:Minoru OkadaMasaya KatoNorifumi SatoTetsuyuki UnoHideki KitagakiJunpei HarutaHidetaka HiyamaTomonori Shibata
A61P 37/08A61P 43/00A61P 37/00A61P 27/16A61P 29/00A61P 25/22A61P 27/02A61P 25/24A61P 25/18A61P 25/16A61P 25/28A61P 17/00A61P 1/04A61P 19/02A61P 11/06A61P 17/06A61P 17/14A61P 11/00A61K 31/421A61K 31/497C12N 9/16A61K 31/496C07D 413/12A61K 31/4439C07D 263/34C07D 263/32A61K 31/422A61K 31/4709C12Y 301/04012C07D 413/06A61K 31/5377
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R 1 is an aryl group which may have one or more substituents; R 2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y 1 -A 1 - or —Y 2 —C(═O)— wherein Y 1 is a group such as —C(═O)—, A 1 is a group such as a lower alkylene group, and Y 2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
Claims
exact text as granted — not AI-modified1 - 14 . (canceled)
15 . A method for obtaining cells expressing phosphodiesterase (PDE) 4, comprising:
preparing a vector containing cDNA encoding human PDE4, introducing the vector into mammalian cells, cultivating the cells in a medium, and collecting the cells
16 . The method of claim 15 , wherein the cells are COS-7 cells.
17 . The method of claim 15 , wherein the vector is a plasmid vector.
18 - 24 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.